Obesity Management

The Signos Glucose Monitoring System uses body signals that help to improve sleep, manage weight, and decrease the risk of chronic disease.

Pharmacists play a key role in guiding patients on GLP-1 and dual agonist therapies, supporting safe use, managing adverse effects, and promoting long-term treatment success.

A phase 2 trial found RDX-002 significantly lowered triglycerides and reduced weight regain in patients who had recently stopped GLP-1 therapy.

Compounding pharmacies help meet patient needs by formulating alternative versions in the face of drug shortages but are no longer allowed to compound them.

Investigators find modest improvements in body weight at week 26 for CT-868 compared with the placebo.

At 72 weeks, patients who took the highest dose of orforglipron lost an average of 27.3 lb.

As part of a retrospective study, researchers explored the association between BMI and osteoporosis risk as outcomes evolve from adolescence to adulthood.

Researchers explored how the GLP-1 medications semaglutide and tirzepatide impact incidence rates in a variety of health-related outcomes.

From 2008 to 2023, the relative increase of pediatric patients with obesity classes 4 to 5 was 253.1%.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Researchers explored patients with type 1 diabetes and overweight or obesity to understand the efficacy and safety of GLP-1s as adjunctive therapies.

Researchers explored the prevalence of obesity-related complications and obesity medication use in US children and young adults with obesity.

Revita is a procedure that modifies duodenal dysfunction and restores metabolic health, according to Fractyl Health.

Pharmaceutical Strategies Group experts joined Drug Topics to discuss the role GLP-1s play in drug benefit design.

In a retrospective study of obesity-related mortality, researchers explored US death trends before, during, and after the COVID-19 pandemic.

In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.

The program will include branded obesity glucagon-like peptide-1 medications, which will have a transparent monthly cost.

Providers can prescribe the 12.5 mg and 15 mg vials of tirzepatide starting July 7, with shipments beginning in early August.

Investigators find that patients with moderate weight loss or those who were weight resistant still had improvement in cardiometabolic health.

Investigators found that simvastatin added to escitalopram for patients with obesity and major depressive disorder did not have increased antidepressive effects.

Results from a phase 2 trial showed that semaglutide combined with trevogrumab, with or without garetosmab, helped patients preserve lean mass and achieve greater fat loss.

The data show a decrease in all-cause mortality for sustained midlife weight loss achieved without surgical or pharmacological interventions.

The new program aims to reduce costs for patients, with savings estimated at as much as $3600 per year.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Investigators report that patients experience weight loss with a reduced weekly dosage of the glucagon-like peptide-1 (GLP-1).